2017 Press Releases
Altimmune Announces $14.7 Million Series B Preferred Stock Offering
August 17, 2017 - GAITHERSBURG, Md., Aug. 17, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced it has entered into a definitive securities purchase agreement with new and existing investors to sell an aggregate of 15,656 shares of Series B convertible preferred stock and warrants. The gross proceeds to the Company are expected to be approximately $14.7 million, before the receipt of proceeds from the exercise of the warrants, if any, and prior ...
Altimmune Announces Second Quarter 2017 Financial Results and Provides Corporate Update
August 10, 2017 - Completed merger with PharmAthene, began trading on NASDAQ as Altimmune, Inc. (ALT)
Remains on track to initiate Phase 2 trial in NasoVAX in Third Quarter
HepTcell Phase 1 clinical trial ongoing in the UK and South Korea, top-line data expected in Fourth Quarter
Conference call and webcast at 8:30 a.m. Eastern time
GAITHERSBURG, Md., Aug. 10, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced financial results for the three...
Altimmune to Announce Second Quarter 2017 Financial Results on August 10
July 31, 2017 - GAITHERSBURG, Md., July 31, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced that it will report financial results for the three and six months ended June 30, 2017 before the market open, and host a conference call at 8:30am Eastern Time on Thursday, August 10th, 2017.
Conference Call Details
Thursday, August 10
8:30am Eastern Time
Altimmune to Provide Corporate Update at the BIO International Convention
June 19, 2017 - Comprehensive, Updated Corporate Presentation Now Available
GAITHERSBURG, Md., June 19, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced that Bill Enright, President and Chief Executive Officer of Altimmune, will present a corporate overview at the BIO International Convention, taking place June 19-22 at the San Diego Convention Center in San Diego, California.
Altimmune Promotes Dr. Sybil Tasker to Chief Medical Officer
May 16, 2017 - GAITHERSBURG, Md., May 16, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced the promotion of Sybil Tasker, M.D., FACP, FIDSA, to the position of Chief Medical Officer. Dr. Tasker joined the company in April 2016 as Senior Vice President, Clinical Research and Development, with responsibility for overseeing Altimmune’s clinical research and development programs.
Bill Enright, President and Chief Executive Officer of Altimmun...
Altimmune, Inc. (Nasdaq: ALT) to Ring The Nasdaq Stock Market Opening Bell
May 10, 2017 - ADVISORY, May 10, 2017 (GLOBE NEWSWIRE) -- What:
Altimmune, Inc. (Nasdaq:ALT), a clinical stage immunotherapeutic biotechnology company, will visit the Nasdaq MarketSite in Times Square.In honor of the occasion, Bill Enright, Chief Executive Officer, will ring the Opening Bell. Where:
Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast StudioWhen:
Friday, May 12, 2017 – 9:15 a.m. to 9:30 a.m. ET Altimmune Contact:
Altimmune Completes Merger with PharmAthene Creating Immunotherapeutics Company Targeting Infectious Diseases
May 04, 2017 - GAITHERSBURG, Md., May 04, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT) announced today the completion of its merger with PharmAthene, Inc., effective May 4, 2017. Upon the completion of the merger, the combined company was renamed Altimmune, Inc., and will commence trading on The NASDAQ Capital Market under the ticker symbol “ALT” on May 5, 2017. The combined company is a fully integrated and diversified immunotherapeutics company with one preclinical-stage and four clinical-stage dr...
PharmAthene and Altimmune Announce Combined Company Approved for Trading on Nasdaq Global Market
April 26, 2017 - ANNAPOLIS, Md. and GAITHERSBURG, Md., April 26, 2017 (GLOBE NEWSWIRE) -- As previously announced, PharmAthene, Inc. (NYSE MKT:PIP) and Altimmune, Inc., a privately-held immunotherapeutics company targeting infectious diseases, have signed a definitive agreement for the merger of PharmAthene and Altimmune in an all-stock transaction. Today, the companies announced that, pending approval of the merger between the two companies by PharmAthene's stockholders at a special meeting of PharmAthene's sto...
Altimmune Receives $7.3 Million Contract Modification from BARDA to Fund Manufacturing of its First-In-Class Anthrax Vaccine Candidate NasoShield™
March 28, 2017 - ...
Altimmune to Present at The Bio Ceo & Investor Conference
February 06, 2017 - ...
Pharmathene and Altimmune Announce Merger to Create Immunotherapeutics Company Targeting Infectious Diseases
January 19, 2017 - ...